Pharmaceutical composition for the treatment of chronic obstructive pulmonary disease and bronchial asthma

A bronchial asthma and chronic obstructive technology, applied in the direction of drug combination, active ingredients of heterocyclic compounds, pharmaceutical formulations, etc., can solve problems such as narrow therapeutic window, achieve the effect of avoiding side effects, reducing side effects, and low price

Inactive Publication Date: 2009-09-16
莫始平
View PDF0 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, using theophylline alone has the disadvantages of a narrow th

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for the treatment of chronic obstructive pulmonary disease and bronchial asthma
  • Pharmaceutical composition for the treatment of chronic obstructive pulmonary disease and bronchial asthma
  • Pharmaceutical composition for the treatment of chronic obstructive pulmonary disease and bronchial asthma

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0063] Embodiment 1 compound prednisone formoterol sheet

[0064] The formula of 1000 tablets of compound prednisone formoterol is:

[0065] Prednisone 1.25g

[0066] Formoterol 0.08g

[0067] Starch 100g

[0068] Microcrystalline Cellulose 50g

[0069] Sodium carboxymethyl starch 20g

[0070] Low-substituted hydroxypropyl cellulose 20g

[0071] 5% povidone ethanol solution 10-20g

[0072] Magnesium Stearate 2g

[0073]Preparation method: crush the raw and auxiliary materials through an 80-mesh sieve, and dry for later use. Take 1.25g of prednisone and 0.08g of formoterol and mix them uniformly according to the method of equal increase, and add starch, microcrystalline cellulose, sodium carboxymethyl starch and low-substituted hydroxypropyl cellulose respectively according to the prescription amount, and Mix uniformly by incremental method, make soft material with 5% povidone ethanol solution, granulate with 20 mesh sieve, dry at 40°C for about 2 hours, granulate with ...

Embodiment 2

[0074] Embodiment 2 prednisone aminophylline compound preparation

[0075] The formula of 1000 prednisone aminophylline compound preparations is:

[0076] Prednisone 3.75g

[0077] Aminophylline 100g

[0078] Microcrystalline Cellulose 40g

[0079] Hypromellose 125g

[0080] Ethyl cellulose 25g

[0081] 5% povidone ethanol solution 20g

[0082] Magnesium Stearate 2g

[0083] Preparation method: crush the raw and auxiliary materials through an 80-mesh sieve, and dry for later use. Take 3.75g of prednisone and 100g of aminophylline and mix uniformly according to the method of equal increase, add microcrystalline cellulose, hypromellose and ethyl cellulose respectively according to the prescription amount, mix evenly according to the method of equal increase, and use Soft material made from 5% povidone ethanol solution, granulated with a 20-mesh sieve, dried at 40°C for about 2 hours, granulated with a 18-mesh sieve, mixed evenly with the dried granules and magnesium stear...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a pharmaceutical composition for the treatment of chronic obstructive pulmonary disease (COPD) and bronchial asthma, which is composed of a glucocorticoid, a bronchodilator and a pharmaceutically acceptable auxiliary material or carrier; the composition is a preparation for oral use. The glucocorticoid in the inventive pharmaceutical composition is selected from prednisone, prednisolone, methylprednisolone, betamethasone, decamethasone or hydrocortisone; the bronchodilator is selected from formoterol, clenbuterol, procaterol or theophylline. The inventive composition has better therapeutic effect on the COPD and the bronchial asthma than independent administration of two ingredients, and has synergistic effect. The composition has easily-available raw materials, inexpensive price and increased medicine taking compliance as well as plays a significant role in preventing and treating the COPD and the bronchial asthma of patients in vast rural areas and patients in low-income class of the city in China.

Description

technical field [0001] The invention relates to a pharmaceutical composition for treating chronic obstructive pulmonary disease (COPD) and bronchial asthma, in particular to a pharmaceutical composition composed of a glucocorticoid (Glucocorticoid) and a bronchodilator (Bronchodilator) and a pharmaceutically acceptable A pharmaceutical composition composed of auxiliary materials or carriers, the composition is in the form of oral preparations. Background technique [0002] Chronic obstructive pulmonary disease (COPD) and bronchial asthma are the two most common and frequently occurring diseases of the respiratory system, among which COPD is a preventable and treatable disease characterized by airflow limitation, which is not completely reversible , which develops progressively and is associated with an abnormal inflammatory response of the lungs to noxious gases or particles. At present, it is generally believed that the mechanism of its occurrence is: chronic inflammation ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K45/06A61P11/06A61P11/00A61K31/573A61K31/137A61K31/167A61K31/522A61K31/52
Inventor 冯玉麟
Owner 莫始平
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap